Shufro Rose & Co. LLC increased its position in CVS Health Corp (NYSE:CVS) by 3.5% during the second quarter, Holdings Channel.com reports. The firm owned 13,103 shares of the pharmacy operator’s stock after buying an additional 439 shares during the quarter. Shufro Rose & Co. LLC’s holdings in CVS Health were worth $714,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Bay Harbor Wealth Management LLC lifted its holdings in shares of CVS Health by 1,871.4% in the 1st quarter. Bay Harbor Wealth Management LLC now owns 552 shares of the pharmacy operator’s stock worth $30,000 after purchasing an additional 524 shares in the last quarter. Manchester Financial Inc. bought a new position in CVS Health during the 2nd quarter valued at $31,000. Murphy Pohlad Asset Management LLC bought a new position in CVS Health during the 4th quarter valued at $39,000. C J Advisory Inc bought a new position in CVS Health during the 1st quarter valued at $33,000. Finally, Capital Financial Planning LLC bought a new position in CVS Health during the 4th quarter valued at $44,000. Institutional investors own 77.33% of the company’s stock.
CVS stock traded down $0.94 during mid-day trading on Monday, reaching $54.77. 4,085,289 shares of the company traded hands, compared to its average volume of 7,517,661. The company has a quick ratio of 0.64, a current ratio of 0.95 and a debt-to-equity ratio of 1.45. The stock has a market capitalization of $72.37 billion, a P/E ratio of 7.74, a P/E/G ratio of 1.25 and a beta of 0.90. CVS Health Corp has a 52-week low of $51.72 and a 52-week high of $82.15. The company has a fifty day moving average price of $55.36.
Several equities analysts have weighed in on CVS shares. UBS Group dropped their price objective on CVS Health from $74.00 to $67.00 and set a “sell” rating on the stock in a research note on Thursday, May 2nd. Bank of America restated a “buy” rating and set a $74.00 price objective (down from $82.00) on shares of CVS Health in a research note on Wednesday, April 10th. Standpoint Research upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Wednesday, June 5th. SunTrust Banks dropped their price objective on CVS Health from $85.00 to $65.00 in a research note on Wednesday, April 10th. Finally, Barclays set a $73.00 price objective on CVS Health and gave the company a “buy” rating in a research note on Thursday, April 11th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $76.48.
About CVS Health
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Recommended Story: Inflation
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.